Patents by Inventor Florian Sennlaub

Florian Sennlaub has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AN INSULIN SENSITIZER FOR USE IN THE PREVENTION AND/OR TREATMENT OF THE DAMAGES CAUSED BY RETINAL DETACHMENT
    Publication number: 20230172919
    Abstract: An insulin sensitizer for use in the prevention and/or treatment of the damages caused by retinal detachment, and in particular for preventing or treating the loss of vision induced by retinal detachment. Also, a composition including the insulin sensitizer for use in the prevention and/or treatment of the damages caused by retinal detachment and a device including the composition.
    Type: Application
    Filed: March 26, 2021
    Publication date: June 8, 2023
    Applicants: SORBONNE UNIVERSITE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Florian SENNLAUB, Jean-Baptiste CONART, José-Alain SAHEL
  • Lebecetin, a C-type lectin, as neovascularization inhibitor
    Patent number: 11191807
    Abstract: The present invention relates to lebecetin, a functional variant or fragment thereof, for use as neovascularization inhibitor, in particular in the treatment of neovascular diseases such as ocular diseases, cancers or inflammatory disorders with a neovascular component.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: December 7, 2021
    Assignees: SARBONNE INIVERSIÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE), INSTITUT PASTEUR DE TUNIS
    Inventors: Xavier Guillonneau, Fadoua Montassar, Naziha Marrakchi, Erij Messadi, Florian Sennlaub, José-Alain Sahel
  • Agents that activate CD47 and their use in the treatment of inflammation
    Patent number: 11142548
    Abstract: Disclosed are agents activating CD47 and their use in the treatment of inflammation, in particular non-resolving low grade inflammation, characterized by chronic MP infiltration, such as age-related macular degeneration. Also disclosed are pharmaceutical compositions, medicaments and kits including the agents.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: October 12, 2021
    Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: Florian Sennlaub, Michael Housset, Xavier Guillonneau, José-Alain Sahel, Philippe Karoyan
  • Agents that inhibit the binding of CFH to CD11 b/CD18 and uses thereof
    Patent number: 11072661
    Abstract: Disclosed are agents inhibiting the interaction between CFH and CD11b/18, as well as the use of such agents, in particular for treating inflammatory disorders, such as age-related macular degeneration.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: July 27, 2021
    Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Florian Sennlaub, Bertrand Callippe, Xavier Guillonneau, José-Alain Sahel
  • Agents for use in the treatment of retinal inflammation
    Patent number: 10519232
    Abstract: The present invention relates to preventive and/or therapeutic agents for use in the treatment of retinal inflammation, and more specifically of Age-related macular degeneration and Retinitis pigmentosa, wherein said agents are selected from an IL-6 inhibitor, an APOE inhibitor and/or a Fas activator as an active ingredient.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: December 31, 2019
    Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Florian Sennlaub, Xavier Guillonneau, Olivier Levy, José-Alain Sahel
  • LEBECETIN, A C-TYPE LECTIN, AS NEOVASCULARIZATION INHIBITOR
    Publication number: 20190298797
    Abstract: The present invention relates to lebecetin, a functional variant or fragment thereof, for use as neovascularization inhibitor, in particular in the treatment of neovascular diseases such as ocular diseases, cancers or inflammatory disorders with a neovascular component.
    Type: Application
    Filed: December 12, 2017
    Publication date: October 3, 2019
    Inventors: XAVIER GUILLONNEAU, FADOUA MONTASSAR, NAZIHA MARRAKCHI, ERIJ MESSADI, FLORIAN SENNLAUB, JOSÉ-ALAIN SAHEL
  • AGENTS THAT ACTIVATE CD47 AND THEIR USE IN THE TREATMENT OF INFLAMMATION
    Publication number: 20190225649
    Abstract: Disclosed are agents activating CD47 and their use in the treatment of inflammation, in particular non-resolving low grade inflammation, characterized by chronic MP infiltration, such as age-related macular degeneration. Also disclosed are pharmaceutical compositions, medicaments and kits including the agents.
    Type: Application
    Filed: May 10, 2017
    Publication date: July 25, 2019
    Inventors: Florian SENNLAUB, Michael HOUSSET, Xavier GUILLONNEAU, José-Alain SAHEL, Philippe KAROYAN
  • CCR2 antagonist peptides
    Patent number: 10253087
    Abstract: The invention relates to a peptide useful as a CCR2 non-competitive antagonist peptide.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: April 9, 2019
    Assignee: Sorbonne University
    Inventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvian Chemtob, Christiane Quiniou
  • AGENTS THAT INHIBIT THE BINDING OF CFH TO CD11b/CD18 AND USES THEREOF
    Publication number: 20190010235
    Abstract: Disclosed are agents inhibiting the interaction between CFH and CD11b/18, as well as the use of such agents, in particular for treating inflammatory disorders, such as age-related macular degeneration.
    Type: Application
    Filed: December 23, 2016
    Publication date: January 10, 2019
    Inventors: Florian SENNLAUB, Bertrand CALLIPPE, Xavier GUILLONNEAU, José-Alain SAHEL
  • CCR2 ANTAGONIST PEPTIDES
    Publication number: 20180251523
    Abstract: The invention relates to a peptide comprising the following amino acid sequence useful as a CCR2 non competitive antagonist peptide.
    Type: Application
    Filed: May 1, 2018
    Publication date: September 6, 2018
    Applicant: UNIVERSITE PIERRE ET MARIE CURIE (Paris 6)
    Inventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvian Chemtob, Christiane Quiniou
  • Azapeptides as CD36 binding compounds
    Patent number: 9708370
    Abstract: An azapeptide compound of Formula I: A-(Xaa)a-N(RA)—N(RB)—C(O)-(Xaa?)b-B ??I.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: July 18, 2017
    Assignees: VALORISATION-RECHERCHE, LIMITED PARTNERSHIP, VALORISATION HSJ, LIMITED PARTNERSHIP
    Inventors: Huy Ong, Sylvain Chemtob, William Lubell, Florian Sennlaub, Damien Boeglin, Caroline Proulx, Zohreh Sajjadi, David Sabatino
  • CCR2 ANTAGONIST PEPTIDES
    Publication number: 20170051040
    Abstract: The invention relates to a peptide comprising the following amino acid sequence Thr-Phe-Leu-Lys or Thr-Phe-Leu-Lys-Cys, useful as a CCR2 non competitive antagonist peptide.
    Type: Application
    Filed: September 2, 2016
    Publication date: February 23, 2017
    Applicant: UNIVERSITE PIERRE ET MARIE CURIE (Paris 6)
    Inventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvain Chemtob, Christiane Quiniou
  • AGENTS FOR USE IN THE TREATMENT OF RETINAL INFLAMMATION
    Publication number: 20160340424
    Abstract: The present invention relates to preventive and/or therapeutic agents for use in the treatment of retinal inflammation, and more specifically of Age-related macular degeneration and Retinitis pigmentosa, wherein said agents are selected from an IL-6 inhibitor, an APOE inhibitor and/or a Fas activator as an active ingredient.
    Type: Application
    Filed: January 22, 2015
    Publication date: November 24, 2016
    Applicants: UNIVERSITÉ PIERRE ET MARIE CURIE - PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Florian SENNLAUB, Xavier GUILLONNEAU, Olivier LEVY, José-Alain SAHEL
  • CCR2 antagonist peptides
    Patent number: 9434766
    Abstract: The invention relates to a peptide comprising the following amino acid sequence Thr-Phe-Leu-Lys (SEQ ID NO: 17) or Thr-Phe-Leu-Lys-Cys (SEQ ID NO: 1), useful as a CCR2 non-competitive antagonist peptide.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: September 6, 2016
    Assignee: Universite Pierre Et Marie Curie (Paris 6)
    Inventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvian Chemtob, Christiane Quiniou
  • AZAPEPTIDES AS CD36 BINDING COMPOUNDS
    Publication number: 20150329591
    Abstract: An azapeptide compound of Formula I: A-(Xaa)a-N(RA)—N(RB)—C(O)-(Xaa?)b-B
    Type: Application
    Filed: July 28, 2015
    Publication date: November 19, 2015
    Inventors: Huy ONG, Sylvain CHEMTOB, William LUBELL, Florian SENNLAUB, Damien BOEGLIN, Caroline PROULX, Zohreh SAJJADI, David SABATINO
  • Azapeptides as CD36 binding compounds
    Patent number: 9115171
    Abstract: An azapeptide compound of Formula I: A-(Xaa)a-N(RA)—N(RB)—C(O)-(Xaa?)b-B??I.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 25, 2015
    Assignees: VALORISATION-RECHERCHE, LIMITED PARTNERSHIP, VALORISATION HSJ, LIMITED PARTNERSHIP
    Inventors: Huy Ong, Sylvain Chemtob, William Lubell, Florian Sennlaub, Damien Boeglin, Caroline Proulx, Zohreh Sajjadi, David Sabatino
  • CCR2 ANTAGONIST PEPTIDES
    Publication number: 20150011477
    Abstract: The invention relates to a peptide comprising the following amino acid sequence Thr-Phe-Leu-Lys or Thr-Phe-Leu-Lys-Cys, useful as a CCR2 non competitive antagonist peptide.
    Type: Application
    Filed: June 26, 2012
    Publication date: January 8, 2015
    Applicant: UNIVERSITE PIERRE ET MARIE CURIE
    Inventors: Christophe Combadiere, Florian Sennlaub, Constance Auvynet, Sylvain Chemtob, Christiane Quiniou
  • Methods for modulating angiogenesis via dystrophin Dp71
    Patent number: 8603964
    Abstract: The present invention relates to methods and compositions for inhibiting or stimulating angiogenesis. The invention shows the implication of Dp71 in angiogenesis and thus provides novel therapeutic approaches, as well as novel methods for screening agents modulating angiogenesis, which target this protein. More specifically, the present invention relates to the use of Dp71 or a variant thereof (or a coding nucleic acid) for stimulating angiogenesis in a subject, particularly a human subject. The invention relates to the use of an inhibitor of Dp71 for inhibiting angiogenesis in a subject.
    Type: Grant
    Filed: July 3, 2009
    Date of Patent: December 10, 2013
    Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Romain Bernard, Bénédicte Dupas, Alain Gaudric, Serge Picaud, Alvaro Rendon, José-Alain Sahel, Abdoulaye Sene, Florian Sennlaub, Ramin Tadayoni, Eric Vicaut
  • AZAPEPTIDES AS CD36 BINDING COMPOUNDS
    Publication number: 20130203686
    Abstract: An azapeptide compound of Formula I: A-(Xaa)a-N(RA)—N(RB)—C(O)-(Xaa?)b—B??I.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 8, 2013
    Inventors: Huy Ong, Sylvain Chemtob, William Lubell, Florian Sennlaub, Damien Boeglin, Caroline Proulx, Zohreh Sajjadi, David Sabatino
  • Azapeptides as CD36 binding compounds
    Patent number: 8435954
    Abstract: An azapeptide derivative of growth hormone releasing peptide (GHRP) of Formula I: A-(Xaa)a-N(RA)—N(RB)—C(O)-(Xaa?)b-B which binds to CD 36.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: May 7, 2013
    Assignees: Valorisation-Recherche, Limited Partnership, Valorisation HSJ, Limited Partnership
    Inventors: Huy Ong, Sylvain Chemtob, William Lubell, Florian Sennlaub, Damien Boeglin, Caroline Proulx, Zohreh Sajjadi, David Sabatino